Atria: A comprehensive evaluation with echocardiography

Baysan, Oben; Ocaklı, Ezgi Polat; Altuner, Tuğba Kayhan; Kocaman, Sinan Altan

doi:10.24969/hvt.2017.8

Cited by 5 publications

(3 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Images were captured and measures made at 3 different points in the beat cycle using Vevo LAB v5.7.1 software. Volume-derived measures of atrial function were calculated using the equations in the Table below following nomenclature in Baysan et al [ 23 ]. LA volume (LAV) pre atrial contraction (pre-A): (LAV preA ) was measured at p-wave onset, LAV minimum (LAV min ) measured at the R-wave, LAV maximum (LAV max ) measured one frame prior to the mitral valve opening.…”

Section: Methodsmentioning

confidence: 99%

Distinct functional and molecular profiles between physiological and pathological atrial enlargement offer potential new therapeutic opportunities for atrial fibrillation

Chen,

Wijekoon,

Matsumoto

et al. 2024

Clinical Science

View full text Add to dashboard Cite

Atrial fibrillation (AF) remains challenging to prevent and treat. A key feature of AF is atrial enlargement. However, not all atrial enlargement progresses to AF. Atrial enlargement in response to physiological stimuli such as exercise is typically benign and reversible. Understanding the differences in atrial function and molecular profile underpinning pathological and physiological atrial remodelling will be critical for identifying new strategies for AF. The discovery of molecular mechanisms responsible for pathological and physiological ventricular hypertrophy has uncovered new drug targets for heart failure. Studies in the atria have been limited in comparison. Here, we characterised mouse atria from 1) a pathological model (cardiomyocyte-specific transgenic (Tg) that develops dilated cardiomyopathy [DCM] and AF due to reduced protective signalling [PI3K]; DCM-dnPI3K), and 2) a physiological model (cardiomyocyte-specific Tg with an enlarged heart due to increased insulin-like growth factor 1 receptor; IGF1R). Both models presented with an increase in atrial mass, but displayed distinct functional, cellular, histological and molecular phenotypes. Atrial enlargement in the DCM-dnPI3K Tg, but not IGF1R Tg, was associated with atrial dysfunction, fibrosis and a heart failure gene expression pattern. Atrial proteomics identified protein networks related to cardiac contractility, sarcomere assembly, metabolism, mitochondria, and extracellular matrix which were differentially regulated in the models; many co-identified in atrial proteomics data sets from human AF. In summary, physiological and pathological atrial enlargement are associated with distinct features, and the proteomic dataset provides a resource to study potential new regulators of atrial biology and function, drug targets and biomarkers for AF.

show abstract

Section: Methodsmentioning

confidence: 99%

Distinct functional and molecular profiles between physiological and pathological atrial enlargement offer potential new therapeutic opportunities for atrial fibrillation

Chen,

Wijekoon,

Matsumoto

et al. 2024

Clinical Science

View full text Add to dashboard Cite

show abstract

“…According to the guideline, LA enlargement was classi ed as a volume index greater than 34 ml/m2 in men and 29 ml/m2 in women. RA volume index cut-off values of 23 ml/m2 in men and 19 ml/m2 in women were also considered RA (Baysan, Ocaklı et al 2017).…”

Section: Study Protocolmentioning

confidence: 99%

Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting: A double-blind, randomized, placebo-controlled trial

zarei,

Fazli,

Tayyebi

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose This study aimed to evaluate the effect of empagliflozin in preventing atrial fibrillation after coronary artery bypass grafting (CABG). Methods Eighty-two patients who fulfilled the inclusion criteria were allocated to the empagliflozin group (n = 43) or placebo group (n = 39). In two groups, patients received empagliflozin or placebo tablets three days before surgery and on the first three postoperative days (for six days) in addition to the standard regimen during hospitalization. During the first three days after surgery, types of arrhythmias after cardiac surgery, including supraventricular arrhythmias, especially postoperative atrial fibrillation (POAF), ventricular arrhythmias, and heart blocks, were assessed by electrocardiogram monitoring. C-reactive protein (CRP) levels were evaluated on the pre-operatively and postoperative third day. Results The incidence of POAF in the treatment group was lower compared to the control group; however, this reduction was statistically non-significant (p = 0.09). The frequency of ventricular tachycardia reduced significantly in the treatment group versus patients in the control (p = 0.02). Also, a significant reduction in the frequency of premature ventricular contractions (PVCs) was seen in the treatment group in comparison with the control group (p = 0.001). After the intervention, CRP levels were significantly less in the empagliflozin group in the control group in the third postoperative day (p = 0.04). Conclusion The prophylactic use of empagliflozin effectively reduced the incidence of ventricular arrhythmia in patients undergoing heart surgeries.

show abstract

“…Magnetic resonance imaging (MRI) is the preferred imaging method for RV evaluation (1) however echocardiography is the most frequently used one due to its widespread availability, safety, repeatability, and real time imaging with high temporal and spatial resolution (2). In our previous reviews in depth analysis of left ventricle and left atrium were discussed (3,4). Here in this mini review we will focus on echocardiographic deformation imaging of the right ventricle and its derived parameters.…”

Section: Introductionmentioning

confidence: 99%